Liesa Regner-Nelke, Marc Pawlitzki, Alice Willison, Leoni Rolfes, Sinem-Hilal Oezalp, Christopher Nelke, Tristan Kölsche, Melanie Korsen, Matthias Grothe, Sergiu Groppa, Felix Luessi, Sinah Engel, Gereon Nelles, Eckhard Bonmann, Holger Roick, Anke Friedrich, Philipp Knorn, Harald Landefeld, Zoltan Biro, Michael Ernst, Antonios Bayas, Martina Menacher, Katja Akgün, Christoph Kleinschnitz, Tobias Ruck, Tjalf Ziemssen, Refik Pul, Sven G Meuth
BACKGROUND: Therapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing-remitting MS, whereas few therapies are available for progressive forms of MS, in particular secondary progressive MS (SPMS). The approval of siponimod for SPMS has allowed for optimism in the otherwise discouraging therapeutic landscape. METHODS: We conducted a retrospective, multicenter, non-interventional study analyzing the efficacy and safety of siponimod under real-world conditions in 227 SPMS patients...
November 7, 2022: Neurological research and practice